Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: | Active, not recruiting |
---|---|
Conditions: | Breast Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 1/11/2017 |
Start Date: | June 2007 |
End Date: | June 2017 |
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
The purpose of this research study is to :
- Determine how effective cisplatin or carboplatin is in slowing the time it takes for ER
negative, PR negative, HER2 negative breast cancer to progress. Cisplatin and
carboplatin are anti-cancer chemotherapy drugs that stop cancer cells from growing
abnormally and is used to treat other cancers.
- Evaluate a new biomarker to help determine which breast cancers are most likely to
respond to cisplatin chemotherapy
The hypothesis is that Triple Negative metastatic breast cancer may be particularly
sensitive to platinum, and that a subgroup of those patients may have a marker in their
tumors that predicts response.
- Determine how effective cisplatin or carboplatin is in slowing the time it takes for ER
negative, PR negative, HER2 negative breast cancer to progress. Cisplatin and
carboplatin are anti-cancer chemotherapy drugs that stop cancer cells from growing
abnormally and is used to treat other cancers.
- Evaluate a new biomarker to help determine which breast cancers are most likely to
respond to cisplatin chemotherapy
The hypothesis is that Triple Negative metastatic breast cancer may be particularly
sensitive to platinum, and that a subgroup of those patients may have a marker in their
tumors that predicts response.
This study is a Phase 2 study designed to evaluate cisplatin/carboplatin as first or second
line therapy in metastatic triple negative (ER negative, PR negative, Her2 Negative) breast
cancer and to evaluate the expression of p63/p73 as a biomarker to predict response.
- Participants will be given a cisplatin or carboplatin infusion intravenously on the
first day of each treatment cycle. Each treatment cycle will last 3 weeks. Treating
physician will select agent up to 41 patients in each cohort. Final primary endpoint
analysis will use combined cis/carbo results.
- During all treatment cycles participants will have a physical exam (including weight
and vital signs) and they will be asked general questions about their health and any
medications they may be taking, as well as specific questions about any side effects
they may be experiencing while receiving study treatment.
- During every treatment cycle participants will have standard blood tests to check blood
counts, liver and kidney function, and a blood marker for you particular type of
cancer.
- CT scans will be taken of the participants tumor every 2 to 3 cycles to assess the
response of the tumor to cisplatin.
- Participants will be in this study for as long as they tolerate the study treatment and
their disease does not get any worse.
- Participants will be required to have a sample of their original tumor sent to
Massachusetts General Hospital for correlative studies, or a sample from a metastatic
diagnostic biopsy.
- Patients with accessible tumor will be asked to provide an optional metastatic tumor
biopsy for correlative studies.
line therapy in metastatic triple negative (ER negative, PR negative, Her2 Negative) breast
cancer and to evaluate the expression of p63/p73 as a biomarker to predict response.
- Participants will be given a cisplatin or carboplatin infusion intravenously on the
first day of each treatment cycle. Each treatment cycle will last 3 weeks. Treating
physician will select agent up to 41 patients in each cohort. Final primary endpoint
analysis will use combined cis/carbo results.
- During all treatment cycles participants will have a physical exam (including weight
and vital signs) and they will be asked general questions about their health and any
medications they may be taking, as well as specific questions about any side effects
they may be experiencing while receiving study treatment.
- During every treatment cycle participants will have standard blood tests to check blood
counts, liver and kidney function, and a blood marker for you particular type of
cancer.
- CT scans will be taken of the participants tumor every 2 to 3 cycles to assess the
response of the tumor to cisplatin.
- Participants will be in this study for as long as they tolerate the study treatment and
their disease does not get any worse.
- Participants will be required to have a sample of their original tumor sent to
Massachusetts General Hospital for correlative studies, or a sample from a metastatic
diagnostic biopsy.
- Patients with accessible tumor will be asked to provide an optional metastatic tumor
biopsy for correlative studies.
Inclusion Criteria:
- Histologically confirmed invasive breast cancer with stage IV disease, according to
AJCC 6th edition, either biopsy proven or with unequivocal evidence of metastatic
disease by physical examination or radiological study
- All tumors must be ER-, PGR- and HER2-negative
- 18 years of age or older
- Paraffin tissue block is required from the primary tumor tissue or from diagnostic
metastatic biopsy at time of relapse
- Measurable disease by RECIST
- Performance status of 0,1 or 2 by ECOG criteria
- Life expectancy greater than 12 weeks
- Normal organ and bone marrow function documented within 14 days prior to enrollment
as defined by the protocol
Exclusion Criteria:
- More than 1 prior chemotherapy for the treatment of recurrent or metastatic breast
cancer
- Prior treatment with cisplatin, carboplatin, or other platinum chemotherapy agents
- Active brain metastases or unevaluated neurological symptoms suggestive of brain
metastases
- Intercurrent illness or other major medical condition or comorbid condition that
might affect study participation
- Significant history of uncontrolled cardiac disease such as uncontrolled
hypertension, unstable angina, recent myocardial infarction, uncontrolled congestive
heart failure, cardiomyopathy either symptomatic or asymptomatic but with decreased
ejection fraction <45%
- Renal dysfunction for which cisplatin dose would either require dose modification or
would be considered unsafe
- Pregnant or nursing women
- History or other malignancy that was not treated with curative intent
We found this trial at
10
sites
Click here to add this to my saved trials
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
Click here to add this to my saved trials
Click here to add this to my saved trials
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Univ of North Carolina Carolina’s vibrant people and programs attest to the University’s long-standing place...
Click here to add this to my saved trials
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials